Table 2

CSF characteristics at the time of the CellSearch® technology analysis
Inclusion number, date of CSF sampling Treatment received for LM at the time of CSF sampling for CVT Biochemical CSF analysis Cytomorphological CSF analysis Enumeration of CSFTC with the CellSearch® Veridex technology
03 - 01 IV paclitaxel for 2 months then Proteinorachia: 0.22 g/L No malignant cell (10 mL) 0 CSFTC per mL
carboplatin Glycorachia: 3.5 mmol/L
No IT chemotherapy Chlorurorachia: 121 mol/L
05 - 01 IV paclitaxel since LM diagnosis Proteinorachia: 1.13 g/L Presence of malignant cells (10 mL) 626 CSFTC per mL
No IT chemotherapy Glycorachia: 2.4 mmol/L
Chlorurorachia: 121 mol/L
05 - 02 IV paclitaxel since LM diagnosis Proteinorachia: 1.42 g/L Presence of malignant cells (10 mL) 1600 CSFTC per mL
No IT chemotherapy Glycorachia: 1.8 mmol/L
Chlorurorachia: 117 mol/L
05 - 03 IV paclitaxel since LM diagnosis Proteinorachia: 2.90 g/L No malignant cell (10 mL) 2100 CSFTC per mL
No IT chemotherapy Glycorachia: 0.3 mmol/L
Chlorurorachia: 118 mol/L
06 - 01 None Proteinorachia: 0.51 g/L Presence of malignant cells (3 mL) 7 CSFTC per mL
Glycorachia: 3.7 mmol/L
Chlorurorachia: 126 mol/L
09 - 01 None Proteinorachia: 1.90 g/L Presence of malignant cells (6 mL) 208 CSFTC per mL
Glycorachia: 3.3 mmol/L
Chlorurorachia: 110 mol/L
09 - 02 Oral vinorelbine Proteinorachia: 1.64 g/L Not interpretable (10 mL) 130 CSFTC per mL
IT liposomal cytarabine (X1) Glycorachia: 4.9 mmol/L
Chlorurorachia: 108 mol/L
09 -03 Oral navelbine Proteinorachia: NA Presence of malignant cells (10 mL) 75 CSFTC per mL
IT liposomal cytarabine (X2) Glycorachia: NA
Chlorurorachia: NA
09 -04 Oral navelbine Proteinorachia: 1.88 g/L Presence of malignant cells (10 mL) 82 CSFTC per mL
IT liposomal cytarabine (X3) Glycorachia: 4.5 mmol/L
Chlorurorachia: 116 mol/L
10 - 01 None Proteinorachia: 0.80 g/L Presence of malignant cells (5 mL) 0.2 CTC per mL
Glycorachia: 3.4 mmol/L
Chlorurorachia: 121 mol/L
10 - 02 FEC 50 Proteinorachia: 0.90 g/L Presence of malignant cells (6 mL) 0.4 CSFTC per mL
IT liposomal cytarabine (X1) Glycorachia: 3.2 mmol/L
Chlorurorachia: 120 mol/L
11 - 01 None Proteinorachia: 7.08 g/L Presence of malignant cells (6 mL) 478 CSFTC per mL
Glycorachia: 2 mmol/L
Chlorurorachia: 113 mol/L
11 - 02 Capecitabine Proteinorachia: 9.04 g/L Presence of malignant cells (8 mL) 940 CSFTC per mL
No IT chemotherapy Glycorachia: 3.2 mmol/L
Chlorurorachia: 100 mol/L
12 - 01 None Proteinorachia: 0.39 g/L Presence of malignant cells (10 mL) 5 CSFTC per mL
Glycorachia: 5.4 mmol/L
Chlorurorachia: 119 mol/L
12 - 02 Oral capecitabine + lapatinib Proteinorachia: 0.21 g/L No malignant cells (8 mL) 0 CSFTC per mL
IT liposomal cytarabine (X1) Glycorachia: 5.4 mmol/L
Chlorurorachia: 119 mol/L
13 - 01 None Proteinorachia: 8.84 g/L Presence of malignant cells (7 mL) 1560 CSFTC per mL
Glycorachia: 2.4 mmol/L
Chlorurorachia: 106 mol/L

LM Leptomeningeal Metastasis, CSF CerebroSpinal Fluid, CSFTC CSF Tumor Cells, IT IntraThecal, IV IntraVenous, FEC Fluorouracil Epirubicin Cyclophosphamide, CVT CellSearch® Veridex Technology, NA Not Available.

Le Rhun et al.

Le Rhun et al. BMC Clinical Pathology 2012 12:21   doi:10.1186/1472-6890-12-21

Open Data